Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Multicenter, Single-arm, Open-label, Phase 4 Study to Evaluate the Effects of Macitentan on Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension Assessed by Cardiac Magnetic Resonance Imaging

Next Previous
Trial Profile

A Prospective, Multicenter, Single-arm, Open-label, Phase 4 Study to Evaluate the Effects of Macitentan on Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension Assessed by Cardiac Magnetic Resonance Imaging

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Macitentan (Primary) ; Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Indications Pulmonary arterial hypertension
  • Focus Therapeutic Use
  • Acronyms REPAIR
  • Sponsors Actelion Pharmaceuticals

    • Most Recent Events

    • 17 May 2021 Results of an analysis assessing the compare standardized treatment effect sizes (STES) of cMRI, hemodynamic and functional endpoints presented at the 70th Annual Scientific Session of the American College of Cardiology
    • 21 Oct 2020 Results from REPAIR ECHO substudy presented at the CHEST Annual Meeting 2020 by Annual Meeting of the American College of Chest Physicians
    • 24 Sep 2020 Results published in the ClinicalTrials.gov Trial Registry
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top